Beta Drugs Limited

Informe acción NSEI:BETA

Capitalización de mercado: ₹20.6b

Beta Drugs Dirección

Dirección controles de criterios 4/4

El CEO de Beta Drugs es Rahul Batra , nombrado en Jan 2021, tiene una permanencia de 3.83 años. compensación anual total es ₹12.10M, compuesta por 100% salario y 0% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.41% de las acciones de la empresa, por valor de ₹84.99M. La antigüedad media del equipo directivo y de la junta directiva es de 3.8 años y 7.3 años, respectivamente.

Información clave

Rahul Batra

Chief Executive Officer (CEO)

₹12.1m

Compensación total

Porcentaje del salario del CEO100.0%
Permanencia del CEO3.8yrs
Participación del CEO0.4%
Permanencia media de la dirección3.8yrs
Promedio de permanencia en la Junta Directiva7.3yrs

Actualizaciones recientes de la dirección

Recent updates

Why Investors Shouldn't Be Surprised By Beta Drugs Limited's (NSE:BETA) 30% Share Price Surge

Nov 08
Why Investors Shouldn't Be Surprised By Beta Drugs Limited's (NSE:BETA) 30% Share Price Surge

Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Aug 30
Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%

Aug 30
Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%

Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%

Dec 23
Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%

Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Dec 11
Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Jul 29
These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching

Jun 17
Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching

Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today

Feb 21
Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today

Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

Dec 20
Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting

Nov 21
With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting

These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Sep 02
These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

May 20
Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

Is Beta Drugs (NSE:BETA) A Risky Investment?

Jan 29
Is Beta Drugs (NSE:BETA) A Risky Investment?

Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Dec 25
Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)

Nov 20
Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Rahul Batra en comparación con los beneficios de Beta Drugs?
FechaCompensación totalSalarioIngresos de la empresa
Sep 30 2024n/an/a

₹410m

Jun 30 2024n/an/a

₹387m

Mar 31 2024₹12m₹12m

₹364m

Dec 31 2023n/an/a

₹356m

Sep 30 2023n/an/a

₹348m

Jun 30 2023n/an/a

₹327m

Mar 31 2023₹12mn/a

₹307m

Dec 31 2022n/an/a

₹298m

Sep 30 2022n/an/a

₹289m

Jun 30 2022n/an/a

₹269m

Mar 31 2022₹8m₹8m

₹248m

Dec 31 2021n/an/a

₹216m

Sep 30 2021n/an/a

₹183m

Jun 30 2021n/an/a

₹150m

Mar 31 2021₹6m₹6m

₹117m

Dec 31 2020n/an/a

₹106m

Sep 30 2020n/an/a

₹95m

Jun 30 2020n/an/a

₹94m

Mar 31 2020₹5m₹5m

₹94m

Sep 30 2019n/an/a

₹97m

Jun 30 2019n/an/a

₹89m

Mar 31 2019₹1m₹1m

₹80m

Compensación vs. Mercado: La compensación total ($USD143.26K) de Rahul está en línea con el promedio de empresas de tamaño similar en el mercado Indian ($USD187.40K).

Compensación vs. Ingresos: La compensación de Rahul ha sido consistente con los resultados de la empresa en el último año.

CEO

Rahul Batra (41 yo)

3.8yrs

Permanencia

₹12,100,000

Compensación

Mr. Rahul Batra serves as the Chairman & Managing Director of Beta Drugs Limited since January 27, 2021. He had been Whole Time Director of Beta Drugs Limited since August 1, 2014 until January 27, 2021. H...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Rahul Batra
Chairman & MD3.8yrs₹12.10m0.41%
₹ 85.0m
Varun Batra
Joint MD & Whole Time Director3.8yrs₹12.10m0.35%
₹ 71.2m
Nipun Arora
Chief Financial Officer3.7yrs₹3.10msin datos
Rajni Brar
Company Secretary & Compliance Officer7.3yrs₹911.55ksin datos
Ashutosh Shukla
VP of Sales & Marketing and Whole Time Director5.7yrs₹5.12msin datos
Seema Chopra
Whole Time Directorno data₹1.19msin datos
Sanjeev Chopra
Vice President of Technicalno datasin datossin datos

3.8yrs

Permanencia media

40.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de BETA se considera experimentado (3.8 años antigüedad media).

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Rahul Batra
Chairman & MD10.3yrs₹12.10m0.41%
₹ 85.0m
Varun Batra
Joint MD & Whole Time Director10.3yrs₹12.10m0.35%
₹ 71.2m
Ashutosh Shukla
VP of Sales & Marketing and Whole Time Director2.8yrs₹5.12msin datos
Seema Chopra
Whole Time Director5.3yrs₹1.19msin datos
Manmohan Khanna
Independent Director7.3yrssin datossin datos
Rohit Parti
Independent Director7.3yrssin datossin datos

7.3yrs

Permanencia media

48yo

Promedio de edad

Junta con experiencia: La junta directiva de BETA se considera experimentada (7.3 años de antigüedad promedio).